אסיף מאגר המחקר החקלאי

Elevated Expression of Moesin in Muscular Dystrophies

Year:

2017

Source of publication :

Authors :

Volume :

187

Co-Authors:

Pines, M., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
Levi, O., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
Genin, O., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
Lavy, A., Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel, Department of Animal Sciences, the Hebrew University of Jerusalem, Rehovot, Israel
Angelini, C., Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ospedale S. Camillo, Venice, Italy
Allamand, V., Research Center in Myology, UPMC Univ Paris 06-Inserm Unité Mixte de Recherche en Santé 974, Centre National de la Recherche Scientifique Formation de Recherche en Evolution 3617, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Halevy, O., Department of Animal Sciences, the Hebrew University of Jerusalem, Rehovot, Israel

Facilitators :

Link :

Abstract:

Fibrosis is the main complication of muscular dystrophies. We identified moesin, a member of the ezrin-radixin-moesin family, in dystrophic muscles of mice representing Duchenne and congenital muscular dystrophies (DMD and CMD, respectively) and dysferlinopathy, but not in the wild type. High levels of moesin were also observed in muscle biopsy specimens from DMD, Ullrich CMD, and merosin-deficient CMD patients, all of which present high levels of fibrosis. The myofibroblasts, responsible for extracellular matrix protein synthesis, and the macrophages infiltrating the dystrophic muscles were the source of moesin. Moesin-positive cells were embedded within the fibrotic areas between the myofibers adjacent to the collagen type I fibers. Radixin was also synthesized by the myofibroblasts, whereas ezrin colocalized with the myofiber membranes. In animal models and patients' muscles, part of the moesin was in its active phosphorylated form. Inhibition of fibrosis by halofuginone, an antifibrotic agent, resulted in a major decrease in moesin levels in the muscles of DMD and CMD mice. In summary, the results of this study may pave the way for exploiting moesin as a novel target for intervention in MDs, and as part of a battery of biomarkers to evaluate treatment success in preclinical studies and clinical trials. © 2017 American Society for Investigative Pathology

Note:

Related Files :

תוכן קשור

More details

You may also be interested in